TY - JOUR
T1 - Safety of rush immunotherapy to multiple aeroallergens in an adult population
AU - Harvey, Shelly M.
AU - Laurie, Scot
AU - Hilton, Kathi
AU - Khan, David A.
N1 - Funding Information:
* Pediatric Allergy/Immunology Associates, P.A., Dallas, Texas. † Dallas Allergy and Asthma Center, Dallas, Texas. ‡ Division of Allergy & Immunology, University of Texas Southwestern Medical Center, Dallas, Texas. This study was approved by the Institutional Review Board at the University of Texas Southwestern Medical Center on September 30, 2002 (IRB No. 1002–546). Supported by the Vanberg Family Foundation. Received for publication September 24, 2003. Accepted for publication in revised form December 12, 2003.
PY - 2004/4
Y1 - 2004/4
N2 - Background: Rush immunotherapy has many potential benefits but a higher incidence of systemic reactions compared with traditional immunotherapy. The safety of rush immunotherapy to multiple aeroallergens has not been widely studied. Objective: To examine the safety of rush immunotherapy to multiple aeroallergens in a primarily adult population and to identify risk factors for systemic reactions. Methods: A retrospective review of 65 patients who received rush immunotherapy to multiple aeroallergens in a university-based allergy practice was conducted. All patients were premedicated with prednisone, cetirizine, ranitidine, and zafirlukast or montelukast. Percutaneous skin testing was performed, major allergen content was analyzed in every fourth patient's immunotherapy extract, and systemic reactions were graded. Results: Systemic reactions were observed in 25 patients (38%). All systemic reactions occurred with the final 3 doses of the protocol. Most (72%) occurred after the final dose of the protocol. Nineteen (76%) of the reactions were mild, 5 (20%) were moderate, and 1 (4%) was severe. Systemic reactions were associated with a higher degree of skin test sensitivity and the presence of weed or dog allergen in the extract (vaccine). Conclusions: Rush immunotherapy is associated with a relatively high incidence of systemic reactions, but most reactions are mild and easily treated. The degree of skin sensitivity to the allergens administered and the presence of dog or weed allergen in the extract may be predictors for the development of systemic reactions.
AB - Background: Rush immunotherapy has many potential benefits but a higher incidence of systemic reactions compared with traditional immunotherapy. The safety of rush immunotherapy to multiple aeroallergens has not been widely studied. Objective: To examine the safety of rush immunotherapy to multiple aeroallergens in a primarily adult population and to identify risk factors for systemic reactions. Methods: A retrospective review of 65 patients who received rush immunotherapy to multiple aeroallergens in a university-based allergy practice was conducted. All patients were premedicated with prednisone, cetirizine, ranitidine, and zafirlukast or montelukast. Percutaneous skin testing was performed, major allergen content was analyzed in every fourth patient's immunotherapy extract, and systemic reactions were graded. Results: Systemic reactions were observed in 25 patients (38%). All systemic reactions occurred with the final 3 doses of the protocol. Most (72%) occurred after the final dose of the protocol. Nineteen (76%) of the reactions were mild, 5 (20%) were moderate, and 1 (4%) was severe. Systemic reactions were associated with a higher degree of skin test sensitivity and the presence of weed or dog allergen in the extract (vaccine). Conclusions: Rush immunotherapy is associated with a relatively high incidence of systemic reactions, but most reactions are mild and easily treated. The degree of skin sensitivity to the allergens administered and the presence of dog or weed allergen in the extract may be predictors for the development of systemic reactions.
UR - http://www.scopus.com/inward/record.url?scp=3042810386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042810386&partnerID=8YFLogxK
U2 - 10.1016/S1081-1206(10)61776-0
DO - 10.1016/S1081-1206(10)61776-0
M3 - Article
C2 - 15104192
AN - SCOPUS:3042810386
SN - 1081-1206
VL - 92
SP - 414
EP - 419
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 4
ER -